Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$49.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Merck & Co Inc Reiterates FY 2013 EPS Guidance; Comments On FY, Q3 2013 Charge Guidance


Tuesday, 1 Oct 2013 07:30am EDT 

Merck & Co Inc reiterated its fiscal 2013 non-GAAP (generally accepted accounting principles) earnings per share (EPS) target range of $3.45 to $3.55 and revised its GAAP range to be between $1.58 and $1.82. The Company expects to record charges relating to the new restructuring program of approximately $900 million to $1.1 billion in fiscal 2013, a majority of which will be recorded in the third quarter of 2013. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report EPS of $3.48 for fiscal 2013. 

Company Quote

56.99
-0.42 -0.73%
4:02pm EDT